Halozyme Therapeutics, Inc. (HALO) EPS Estimated At $-0.21 as of May, 8

April 16, 2018 - By Robert Reynolds

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Corporate Logo
During 2017 Q4 the big money sentiment increased to 1.66. That’s change of 0.40, from 2017Q3’s 1.26. 13 investors sold all, 45 reduced holdings as Halozyme Therapeutics, Inc. ratio is positive. 57 increased stakes while 39 funds bought stakes. Funds hold 118.31 million shares thus 0.18% less from 2017Q3’s 118.53 million shares.
Principal Fincl holds 0% or 41,785 shs in its capital. Metropolitan Life Insurance Communication New York stated it has 0.01% in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Kennedy Inc holds 0.18% or 507,978 shs in its capital. National Bank Of America Corp De has invested 0% in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Teacher Retirement Sys Of Texas holds 0.01% of its capital in Halozyme Therapeutics, Inc. (NASDAQ:HALO) for 43,682 shs. Fortaleza Asset Inc holds 1.01% of its capital in Halozyme Therapeutics, Inc. (NASDAQ:HALO) for 7,941 shs. Art Advisors Ltd Llc has invested 0.18% in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Moreover, Legal & General Group Pcl has 0% invested in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Us Bank De accumulated 0% or 4,045 shs. Doheny Asset Mngmt Ca has invested 1.02% in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Vanguard Group owns 11.20 million shs. Cubist Systematic Strategies Limited Com reported 26,290 shs or 0.03% of all its holdings. Millennium Lc invested 0.04% of its capital in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Schwab Charles Investment Inc reported 0.01% of its capital in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Products Prtnrs Limited Liability Corporation has invested 0.24% in Halozyme Therapeutics, Inc. (NASDAQ:HALO).

Halozyme Therapeutics, Inc. (NASDAQ:HALO)’s quarterly earnings will be revealed On May, 8., according to Faxor. Last year’s earnings per share was $-0.26, while now analysts expect change of 19.23 % up from current $-0.21 earnings per share. After $0.85 EPS report last quarter, Wall Street now sees -124.71 % negative EPS growth of Halozyme Therapeutics, Inc.. Its shares touched $19.27 on during the last trading session after 0.52% change.Halozyme Therapeutics, Inc. has volume of 487,551 shares. Since April 17, 2017 HALO has risen 32.10% and is uptrending. The stock outperformed the S&P500 by 20.55%.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Ratings Coverage

In total 6 analysts cover Halozyme Therapeutics (NASDAQ:HALO). “Buy” rating has 3, “Sell” are 0, while 3 are “Hold”. 50% are bullish. 9 are the (NASDAQ:HALO)’s analyst reports since November 8, 2017 according to StockzIntelligence Inc. On Wednesday, November 8 BMO Capital Markets maintained the shares of HALO in report with “Market Perform” rating. In Wednesday, February 21 report Canaccord Genuity maintained it with “Buy” rating and $21.0 target. The stock rating was downgraded by Barclays Capital to “Hold” on Wednesday, November 22. On Wednesday, November 8 the rating was maintained by Canaccord Genuity with “Buy”. On Wednesday, February 21 JP Morgan maintained the shares of HALO in report with “Overweight” rating. On Thursday, February 22 the rating was maintained by BMO Capital Markets with “Market Perform”. On Wednesday, January 24 the stock of Halozyme Therapeutics, Inc. (NASDAQ:HALO) has “Buy” rating given by Deutsche Bank.

Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally.The firm is worth $2.76 billion. The company's human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit.42.82 is the P/E ratio. The Company’s products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.